Alternative palbociclib dosing schedules for hormone receptor-positive and HER2-negative metastatic breast cancer [0.03%]
激素受体阳性且HER2阴性的转移性乳腺癌的帕博西尼替代给药方案
Makiko Go,Michio Kimura,Shiori Yamada et al.
Makiko Go et al.
Introduction: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is associated with a high incidence of neutropenia. Treatment continuation using the standard dosing schedule (3 consecutive weeks of oral a...
Characteristics of HCC patients with portal vein thrombosis: albumin and survival [0.03%]
肝癌合并门静脉血栓患者的临床特征：白蛋白与生存期关系的研究
Brian Carr,Rossella Donghia,Sezai Yilmaz
Brian Carr
Introduction: Presence of macroscopic portal vein thrombosis (PVT) in patients with hepatocellular carcinoma (HCC) has been found to be a major poor prognosis characteristic. ...
Comparing the efficacy of a triplet antiemetic regimen in patients with esophageal cancer patients and diabetes mellitus treated with cisplatin-based chemotherapy: A retrospective study [0.03%]
一项回顾性研究：顺铂为基础的化疗治疗食管癌合并糖尿病患者的三联止吐方案的有效性比较
Masahiro Hatori,Shota Fukuoka,Shunya Kimura et al.
Masahiro Hatori et al.
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytriptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanza...
Survival outcomes of Durvalumab in combination to cisplatin and gemcitabine in advanced biliary tract cancer: real world results from a single Italian institution [0.03%]
Durvalumab联合顺铂和吉西他滨治疗晚期胆道癌的生存结果：来自意大利单中心的真实世界数据
Margherita Rimini,Silvia Foti,Silvia Camera et al.
Margherita Rimini et al.
Introduction: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy...
Diagnostic value of artificial intelligence-based pathology diagnosis system in lymphatic metastasis of gastric cancer [0.03%]
基于人工智能的病理诊断系统在胃癌淋巴结转移中的诊断价值分析
Tiantian Zhao,Qiong Wu,Chenglou Zhu et al.
Tiantian Zhao et al.
Introduction Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, with lymph node metastasis (LNM) being an independent prognostic factor. However, there are still challenges in the pathological diagnosis ...
Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or Without Transarterial Chemoembolization [0.03%]
晚期肝细胞癌联合放化疗的瑞戈非尼治疗：结合或不结合经动脉化疗栓塞术
Lei Cao,Xiangyu Lu,Haoqing Chen et al.
Lei Cao et al.
Introduction: The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting o...
Digitalization and standardization oncology drug therapy plans with the Onkopti database for online publication and import into software [0.03%]
Onkopti数据库的肿瘤药物治疗方案的数字化和标准化并在网上发布以及将数据输入软件中
Hartmut Link,Axel Wickenkamp,Annika Dresel et al.
Hartmut Link et al.
Background Oncological therapy is based on multidimensional therapy protocols. The requirements for standardized protocols and digitation are high. These protocols are created through several complex development stages to ensure standardize...
Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study [0.03%]
质子泵抑制剂与CDK4/6抑制剂在转移性激素受体阳性乳腺癌患者中联用的现实队列研究
Ogur Karhan,Serdar İleri,Zuhat Urakçı et al.
Ogur Karhan et al.
Introduction: Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate w...
Metastatic Patterns: Insights from Japanese Pathological Autopsy Registry Analysis [0.03%]
日本病理尸检登记分析的转移模式：启示
Tomohiko Hara,Suguru Oka,Shinji Ito et al.
Tomohiko Hara et al.
Introduction: Understanding the metastatic patterns is crucial for the treatment of malignancies. This study aimed to identify the characteristic organ metastases of primary malignancies, including rare malignancies, and ...
Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer [0.03%]
基于新型炎症标志物的指数与尼伏单抗治疗复发/转移性头颈部鳞癌疗效的相关性研究
Hiroe Tada,Reika Kawabata-Iwakawa,Hideyuki Takahashi et al.
Hiroe Tada et al.
Introduction: Immune checkpoint inhibitors provide new treatments for patients with recurrent or metastatic (R/M) head and neck cancers. Herein, we focused on systemic inflammatory markers in peripheral blood, including b...